MCP Enters Agreement to Produce Diagnostic Aid

MCP Pharmaceuticals Enters Agreement to Produce Diagnostic Aid

PARSIPPANY, NJ October 18, 2011 — MCP Pharmaceuticals, a provider of global contract manufacturing services for sterile injectable products announced today that it has entered into an agreement with an undisclosed pharmaceutical company for the product transfer and registration batch production of a diagnostic aid. Stuart Hinchen, president and CEO of MCP stated “Our record of cGMP compliance, coupled with comprehensive experience in manufacturing site transfers put us in the position to serve this important customer.”

Commenting on the successful completion of recent FDA and EMA audits in addition to agreements with six new customers, Hinchen noted, “Our Rochester, Michigan site has a 25 year history in contract manufacturing. This accomplishment was created by a quality-driven, experienced staff and a customer-centric approach. Since purchasing the plant in 2007, we have focused on growing our internal infrastructure to support expansion of our contract manufacturing services by investing in both our people and our facilities.

Recent investments include a clinical filler and a 240 sq. ft. lyophilizer in addition to expanding our Manufacturing, Regulatory and Quality Teams.” “MCP Pharmaceuticals has extensive experience working with products throughout their life cycle starting with clinical trial supplies, through regulatory approval, product launch and global commercialization providing customers with the right scale and experience to meet their product life cycle needs.”

About MCP Pharmaceuticals, LLC

MCP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile products including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics and antibiotics for large and small pharmaceutical and biotech organizations. MCP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse.

The production facility utilizes three high-speed filling lines, a clinical filling line and four lyophilizers. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development. MCP has the capability to manufacture small-scale clinical through large-scale commercial products. MCP employs more than 370 staff in the USA in its manufacturing, product development, regulatory, sales and marketing and corporate areas. For more information, please visit jhppharma.com.

Additional Press Releases

04/17/13

MCP Pharmaceuticals To Produce Supplies of Biologic Drug Product For Late-Phase Clinical Trials

Webpage | PDF Format

12/31/12

MCP Pharmaceuticals Acquired By Warburg Pincus

Webpage | PDF Format

09/19/12

MCP Pharmaceuticals To Produce Lyophilized Biologic for International Late-Phase Clinical Trials

Webpage | PDF Format

06/07/12

MCP Pharmaceuticals Launches Generic Division